NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016

Horwitz, Steven M.; Zelenetz, Andrew D.; Gordon, Leo I.; Wierda, William G.; Abramson, Jeremy S.; Advani, Ranjana H.; Andreadis, Charalambos; Bartlett, Nancy L.; Byrd, John C.; Fayad, Luis; Fisher, Richard I.; Glenn, Martha; Habermann, Thomas M.; Harris, Nancy L.; Hernandez‐Ilizaliturri, Francisco J.; Hoppe, Richard T.; Kaminski, Mark; Kelsey, Christopher R.; Kim, Youn H.; Krivacic, Susan; Casce, Ann S. La; Lunning, Matthew A.; Nademanee, Auayporn; Press, Oliver W.; Rabinovitch, Rachel; Reddy, Nishitha; Reid, Erin; Roberts, Kenneth B.; Saad, Ayman; Sokol, Lubomir; Swinnen, Lode J.; Vose, Julie M.; Yahalom, Joachim; Zafar, Nadeem; Dwyer, Mary; Sundar, Hema; Porcu, Pierluigi

doi:10.6004/jnccn.2016.0117

Cited by 113 publications

(122 citation statements)

References 48 publications

Supporting

Mentioning

120

Contrasting

Order By: Relevance

“…Clearly, data from large phase 3 randomized trials are needed to further elucidate the role of upfront ASCT in PTCL, but randomizing patients to an intense therapy such as ASCT versus observation is a formidable task, especially with a rare disease such as PTCL. Despite these limitations, the current National Comprehensive Cancer Network guidelines recommend (category 2A) consideration of ASCT in CR1 for most PTCL subtypes with the notable exceptions of low‐risk ALK‐positive ALCL and extranodal natural killer/T‐cell lymphoma (nasal type) …”

Section: Introductionmentioning

confidence: 99%

“…Despite these limitations, the current National Comprehensive Cancer Network guidelines recommend (category 2A) consideration of ASCT in CR1 for most PTCL subtypes with the notable exceptions of low-risk ALK-positive ALCL and extranodal natural killer/T-cell lymphoma (nasal type). 17 The current study is designed to better our understanding of whether upfront ASCT confers superior survival outcomes to patients with nodal PTCL who achieve CR1. We analyzed a series of prospectively enrolled patients in the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) study, a large national cohort study of patients with newly diagnosed PTCL in the United States.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Park

Horwitz

Foss

et al. 2019

Cancer

Self Cite

115

View full text Add to dashboard Cite

Background The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T‐cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1. Methods Patients with newly diagnosed, histologically confirmed, aggressive PTCL were prospectively enrolled into the Comprehensive Oncology Measures for Peripheral T‐Cell Lymphoma Treatment (COMPLETE) study, and those in CR1 were included in this analysis. Results Two hundred thirteen patients with PTCL achieved CR1, and 119 patients with nodal PTCL, defined as anaplastic lymphoma kinase–negative anaplastic large cell lymphoma, angioimmunoblastic T‐cell lymphoma (AITL), or PTCL not otherwise specified, were identified. Eighty‐three patients did not undergo ASCT, whereas 36 underwent consolidative ASCT in CR1. At the median follow‐up of 2.8 years, the median overall survival was not reached for the entire cohort of patients who underwent ASCT, whereas it was 57.6 months for those not receiving ASCT (P = .06). ASCT was associated with superior survival for patients with advanced‐stage disease or intermediate‐to‐high International Prognostic Index scores. ASCT significantly improved overall and progression‐free survival for patients with AITL but not for patients with other PTCL subtypes. In a multivariable analysis, ASCT was independently associated with improved survival (hazard ratio, 0.37; 95% confidence interval, 0.15‐0.89). Conclusions This is the first large prospective cohort study directly comparing the survival outcomes of patients with nodal PTCL in CR1 with or without consolidative ASCT. ASCT may provide a benefit in specific clinical scenarios, but the broader applicability of this strategy should be determined in prospective, randomized trials. These results provide a platform for designing future studies of previously untreated PTCL.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Park

Horwitz

Foss

et al. 2019

Cancer

Self Cite

115

View full text Add to dashboard Cite

show abstract

“…CECT is routinely included in lymphoma staging due to its robustness in nodal size measurement, evaluation of compression or thrombosis of central vessels, and discrimination between a single mass and an aggregate of single nodes . For surveillance of patients with stage I/II, the National Comprehensive Cancer Network (NCCN) guidelines recommend clinical examination and blood test every 3 to 6 months for 5 years and imaging only if signs of disease relapse occur, whereas CECT every 6 months for 2 years in stage III/IV patients …”

Section: Introductionmentioning

confidence: 99%

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

Albano

Bruno

Patti

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole‐body MRI (WB‐MRI) as a radiation‐free alternative to standard imaging procedures. WB‐MRI seems a less histology‐dependent functional imaging test than 18F‐fluorodeoxyglucose‐positron emission tomography/CT (18F‐FDG‐PET/CT). In patients with FDG‐avid lymphomas, such as diffuse large B‐cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18F‐FDG‐PET/CT remains the imaging reference standard for staging, with WB‐MRI potentially being a complementary modality that could replace CT, especially in young patients. On the other hand, WB‐MRI is a valuable imaging procedure for lymphoma surveillance and in lymphomas with variable/low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to discuss the current state of the art of WB‐MRI in lymphoma by evaluating its diagnostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indolent lymphomas.

show abstract

“…Approximately 85%–90% of NHLs are of B-cell origin, while the remaining NHLs originate from T cells and natural killer (NK) cells 1 . At present, the Ann Arbor staging system and the International Prognostic Index (IPI) are predominantly used to predict NHL prognosis 2 . However, prognosis varies among patients with similar pathological types of NHL and who have received the same treatments.…”

Section: Introductionmentioning

confidence: 99%

The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis

Zhao¹,

Zhang²,

Meng

et al. 2018

Cancer Biology & Medicine

View full text Add to dashboard Cite

Objective:Although the prognostic value of programmed cell death-ligand 1 (PD-L1) expression in non-Hodgkin lymphoma (NHL) has been evaluated in many studies, the results remain controversial. To investigate the prognostic role of PD-L1 expression and the association between PD-L1 expression and clinicopathological features of NHL, we performed a meta-analysis.Methods:The PubMed, EMBASE, and Cochrane Library databases were searched up to November 30, 2017. The hazard ratio (HR), 95% confidence interval (CI), and odds ratios (OR) with 95% CIs were combined to evaluate the association of PD-L1 expression with overall survival (OS) and clinicopathological features. Review manager 5.3 and STATA 12.0 were used in this meta-analysis.Results:A total of 2,005 patients across nine studies were enrolled in our meta-analysis, and the pooled results showed that high PD-L1 expression was associated with a poor prognosis (HR=2.04, 95% CI: 1.18–3.54, P=0.01). In the subgroup analysis according to histology types, pooled results demonstrated that an increased PD-L1 expression was an unfavorable prognostic factor for diffuse large B-cell lymphoma (HR=1.92, 95% CI: 1.06–3.48, P=0.03) but not for natural killer/T-cell lymphoma (HR=2.41, 95% CI: 0.47–12.22, P=0.29). Pooled ORs indicated that PD-L1 expression was higher in NHL with international prognostic indices of ≥3. However, PD-L1 expression had no correlation with gender, age, disease stage, lactate dehydrogenase level, B symptoms, and germinal center B-cell-like lymphoma. Conclusions:High PD-L1 expression was a poor prognostic biomarker in patients with NHL. Because of our limited sample size, high-quality studies with larger sample sizes are needed to validate our results.

show abstract

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016

Cited by 113 publications

References 48 publications

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis

Contact Info

Product

Resources

About